Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 401 to 425 of 872

TitleReference numberPublishedLast updated
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitisTA708
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA709
Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancerTA707
Ozanimod for treating relapsing–remitting multiple sclerosisTA706
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancerTA705
Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal)TA702
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal)TA703
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapiesTA704
Ravulizumab for treating paroxysmal nocturnal haemoglobinuriaTA698
Ofatumumab for treating relapsing multiple sclerosisTA699
Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal)TA701
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapyTA692
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemiaTA694
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myelomaTA695
Acalabrutinib for treating chronic lymphocytic leukaemiaTA689
Avelumab for untreated metastatic Merkel cell carcinomaTA691
Avelumab for treating metastatic Merkel cell carcinomaTA517
Anakinra for treating Still's diseaseTA685
Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)TA686
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA687
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic diseaseTA684
Erenumab for preventing migraineTA682
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancerTA683
Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myelomaTA680
Baricitinib for treating moderate to severe atopic dermatitisTA681

Results per page

  1. 10
  2. 25
  3. 50
  4. All